[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"implantation-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:implantation-failure":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,79],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":5},"100053246","linzagolix-in-adenomyosis-and-recurrent-implantation-failure-100053246",false,"NCT07698561","Linzagolix in Adenomyosis and Recurrent Implantation Failure","Efficacy of Linzagolix 200 mg for 3 to 6 Months Prior to Embryo Transfer in Patients With Adenomyosis and Recurrent Implantation Failure: A Prospective Case Series","LINZA-RIF","Inclusion Criteria:\n\n* Age 18 to 50 years\n* Confirmed adenomyosis by transvaginal ultrasound or MRI\n* Recurrent implantation failure defined as 2 or more failed embryo transfers with high-quality blastocysts: oocyte donation recipients (blastocyst grade BB or above, Gardner classification) OR autologous IVF cycles with PGT-A confirmed euploid blastocysts\n* Normal uterine cavity with no submucosal distortion\n* At least 1 suitable embryo available for transfer (blastocyst grade BB or above, or PGT-A euploid)\n* Signed written informed consent including explicit acknowledgement of off-label use of linzagolix\n\nExclusion Criteria:\n\n* Untreated hydrosalpinx\n* Untreated stage III-IV endometriosis\n* Major uterine anomaly (uterine septum, bicornuate uterus)\n* Known contraindication to linzagolix including known hepatopathy\n* Prior treatment with linzagolix\n* GnRH analogue treatment within 6 months prior to enrolment\n* BMI greater than 35 kg\u002Fm2\n* Prior failed transfers exclusively with embryos below the quality threshold (below BB grade, non-euploid)","FEMALE","18 Years","50 Years",{"count":21,"type":22},35,"ESTIMATED","2 Years","OBSERVATIONAL","Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos. Linzagolix (Yselty, 200 mg) is an oral GnRH receptor antagonist approved for uterine fibroids with a favourable tolerability profile and rapid elimination half-life (18-20 hours) compared to GnRH agonists.\n\nThis prospective case series evaluates the efficacy of linzagolix 200 mg administered for 3 to 6 months prior to embryo transfer in patients with confirmed adenomyosis and recurrent implantation failure (RIF), defined as ≥2 failed transfers with high-quality blastocysts (≥BB Gardner in oocyte donation, or PGT-A confirmed euploid in autologous cycles).\n\nThe primary endpoint is the live birth rate (LBR) per embryo transfer. Secondary endpoints include clinical pregnancy rate, miscarriage rate, morphological response of adenomyosis (uterine volume and junctional zone \\[JZ\\] thickness assessed by standardised transvaginal ultrasound), and tolerability profile. The study also explores the optimal treatment duration (3 vs 6 months) as a sub-analysis based on morphological response at the month-3 visit.\n\nThe study is conducted at three centres of Vida Fertility Institute (Madrid, Alicante and San Sebastián, Spain). Sample size: n=35 patients. Study duration: 24 months.",[27,28,29,30],"Adenomyosis of Uterus","Implantation Failure","Infertility Female","Embryo Transfer",[32,33,34,35,36,37,38,39,40,41],"Linzagolix","Yselty","adenomyosis","recurrent implantation failure","junctional zone","live birth rate","oocyte donation","PGT-A","GnRH antagonist","endometrial receptivity","NOT_YET_RECRUITING","2026-07-06",{"date":45,"type":46},"2026-07-13","ACTUAL",{"date":48,"type":22},"2026-09-01",{"date":50,"type":22},"2028-09-01",{"name":52,"class":53},"Vida Fertility Institute","INDUSTRY",{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":4},"100643882","effects-of-different-acupuncture-techniques-on-the-success-rate-in-patients-with-recurrent-implantation-failure-100643882","NCT07669623","Effects of Different Acupuncture Techniques on the Success Rate in Patients With Recurrent Implantation Failure","Inclusion Criteria:\n\n1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).\n2. Age: 20 to 40 years old.\n3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET).\n4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).\n5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.\n\nExclusion Criteria:\n\n1. Individuals planning to undergo preimplantation genetic diagnosis (PGD).\n2. Recipients of egg donations.\n3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).\n4. Patients with known embryo-related factors leading to implantation failure.\n5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).\n6. Abnormalities in immunity and blood coagulation\n7. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).\n8. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.\n9. Individuals with untreated hydrosalpinx;\n10. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg\u002F m2.\n11. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.","20 Years","40 Years",{"count":63,"type":22},312,"INTERVENTIONAL",[66],"NA","To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of different acupuncture methods on the success rate in patients with recurrent implantation failure",[28],"2026-06-20",{"date":71,"type":46},"2026-06-25",{"date":73,"type":22},"2026-07-01",{"date":75,"type":22},"2029-06-30",{"name":77,"class":78},"Cui Hong Zheng","OTHER",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":17,"minAge":60,"maxAge":61,"enrollmentInfo":86,"targetDuration":4,"studyType":64,"phases":88,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":91,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100630332","effect-of-acupuncture-on-the-success-rate-in-patients-with-recurrent-implantation-failure-100630332","NCT07486297","Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure","A Multicenter Randomized Controlled Trial Evaluating the Effect of Acupuncture on the Success Rate in Patients With Recurrent Implantation Failure","Inclusion Criteria:\n\n1. Meets the criteria for RIF diagnosis (≥ 2 instances of unsuccessful transfer of high-quality embryos).\n2. Age: 20 to 40 years old.\n3. Planning for a cycle involving the transfer of frozen-thawed embryos (FET).\n4. Possession of a transplantable D3 frozen embryo (≥6 cells) or a frozen blastocyst (≥3BC).\n5. Estradiol-progesterone replacement therapy: endometrial thickness ≥ 7 mm within the period of endometrial transformation.\n\nExclusion Criteria:\n\n1. Individuals planning to undergo preimplantation genetic diagnosis (PGD).\n2. Recipients of egg donations.\n3. Chromosomal abnormalities in either spouse or one partner (excluding chromosomal polymorphisms).\n4. Patients with known embryo-related factors leading to implantation failure.\n5. Abnormalities of the uterus that may affect implantation (including uterine malformations, uterine tuberculosis, submucosal myomas, severe uterine adhesions, severe uterine endometriosis, myomas with a diameter of ≥4 cm, and so on).\n6. Recurrent spontaneous abortions (loss of a fetus before 28 weeks of gestation occurring twice or more).\n7. Individuals with other endocrine disorders, such as thyroid disorders, hyperprolactinemia, insulin resistance, diabetes, and adrenal disorders, whose hormone levels have not been well-controlled over the past 3 months.\n8. Individuals with untreated hydrosalpinx;\n9. Individuals with a Body Mass Index (BMI) below 18 and above 25 kg\u002Fm2.\n10. Men with severe abnormalities in semen quality. Individuals with a history of needle phobia.",{"count":87,"type":22},208,[66],"To conduct a multi-center, randomized, controlled clinical study aimed at formally evaluating the impact of pressing therapy on the success rate in patients with recurrent implantation failure.",[28],{"date":71,"type":46},{"date":93,"type":22},"2026-06-30",{"date":95,"type":22},"2028-06-30",{"name":97,"class":78},"Huazhong University of Science and Technology",1]